Experimental research of tankyrase 1 antisense oligodeoxynucleotides on the proliferation of lung cancer cell nodules
Tóm tắt
To observe the effects of sense and antisense oligodeoxynucleotides of tankyrase 1 (TANK1-SODN and TANK1-ASODN) on murine tumor growth following intratumoral injection, investigate the actual suppressing result and mechanism of TANK1-ASODN on cancer cell proliferation, and discuss the possibility of using it in gene therapy on human lung cancer cells. Aft er BALB/c nude mice had been subcutaneously inoculated with human lung cancer cell line CALU and it had grown into tumor nodules, we distributed these mice randomly into 3 groups: 4 in saline treatment group, and 5 each in TANK1-SODN group, and TANK1-ASODN groups. Then multiple direct intratumoral injections of synthesized TANK1-ASODN given continuously into tumor nodules for 16 days, this was compared with TANK1-SODN and saline control groups. During the experiment we measured the tumor volume every 5 days with vernier calipers; observed the histopathological characteristics of tumor tissues under microscope; went further to detect the minute changing of ultrastructure of cancer cells by electron microscope; tested the expression levels of ki67 and hTERT protein by means of SABC immunohistochemical method; and detected the lung cancer cells’ hTERT mRNA expression level by hybridization in situ (ISH) in each group. After 16 days of continuous injection, the tumor volume in TANK1-ASODN group was significantly smaller than the other 2 groups (both P < 0.01); quite a lot of tumor cell degeneration and necrosis were observed in mice given TANK1-ASODN. The results of electron microscope also showed that TANK1-ASODN has the power to kill cancer cells in various ways. Moreover, statistically significant decreases in the positive expression ratio of Ki67 Labeling Index (P < 0.01), hTERT protein (P < 0.01), and hTERT mRNA (P < 0.01) were consistently observed in the TANK1-ASODN group. Human lung cancer cell line CALU expressed high telomerase activity. TANK1-ASODN had the ability to decline the high expression level of hTERT; inhibit the activity of telomerase, accelerate tumor cell degeneration and necrosis; and then suppress the proliferation of cancer cells.
Tài liệu tham khảo
Muñoz P, Blanco R, de Carcer G, et al. TRF1 controls telomere length and mitotic fidelity in epithelial homeostasis. Mol Cell Biol 2009; 29: 1608–1625.
Yoo JE, Oh BK, Park YN. Human PinX1 mediates TRF1 accumulation in nucleolus and enhances TRF1 binding to telomeres. J Mol Biol 2009; 388: 928–940.
White C, Gagnon SN, St-Laurent JF, et al. The DNA damage-inducible C. elegans tankyrase is a nuclear protein closely linked to chromosomes. Mol Cell Biochem 2009; 324: 73–83.
Hsiao SJ, Smith S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie 2008; 90: 83–92.
Donigian JR, de Lange T. The role of the poly (ADP-ribose) polymerase tankyrase1 in telomere length control by the TRF1 component of the shelterin complex. J Biol Chem 2007; 282: 22662–22667.
Seimiya H, Muramatsu Y, Smith S, et al. Functional subdomain in the ankyrin domain of Tankyrase1 required for poly (ADP-ribosyl) ation of TRF1 and telomere elongation. Mol Cell Biol 2004; 24: 1944–1955.
Muramatsu Y, Tahara H, Ono T, et al. Telomere elongation by a mutant tankyrase 1 without TRF1 poly (ADP-ribosyl) ation. Exp Cell Res 2008; 314: 1115–1124.
De Rycker M, Price CM. Tankyrase polymerization is controlled by its sterile alpha motif and poly (ADPribose) polymerase domains. Mol Cell Biol 2004; 24: 9802–9812.
Muramatsu Y, Ohishi T, Sakamoto M, et al. Crossspecies difference in telomeric function of tankyrase 1. Cancer Sci 2007; 98: 850–857.
Donigian JR, de Lange T. The role of the poly (ADP-ribose) polymerase tankyrase1 in telomere length control by the TRF1 component of the shelterin complex. J Biol Chem 2007; 282: 22662–22667.
Sun J, Huang H, Zhu YY. Study on the expression of tankyrase in malignant hematopoietic cells and its relation with telomerase activity. Zhongguo Shiyanxue Zazhi 2004; 12: 11–15 (Chinese).
Klapper W, Krams M, Qian W, et al. Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomerebinding protein expression but uncoupled from proliferation. Br J Cancer 2003; 89: 713–719.
Gelmini S, Poggesi M, Pinzani P, et al. Distribution of Tankyrase-1 mRNA expression in colon cancer and its prospective correlation with progression stage. Oncol Rep 2006; 16: 1261–1266.
Shebzukhov YV, Lavrik IN, Karbach J, et al. Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients. Cancer Immunol Immunother 2008; 57: 871–881.
Gelmini S, Poggesi M, Distante V, et al. Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer. Cancer Lett 2004; 216: 81–87.
Poonepalli A, Banerjee B, Ramnarayanan K, et al. Telomere-mediated genomic instability and the clinicopathological parameters in breast cancer. Genes Chromosomes Cancer 2008; 47: 1098–1109.
Shervington A, Patel R, Lu C, et al. Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res 2007; 1134: 45–52.
Gelmini S, Quattrone S, Malentacchi F, et al. Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience. Clin Chem Lab Med 2007; 45: 862–866.
Chen H, Li Y, Tollefsbol TO. Poly (ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr Pharm Des 2007; 13: 933–962.
Andrews LG, Tollefsbol TO. Methods of telomerase inhibition. Methods Mol Biol 2007; 405: 1–7.
Ohishi T, Tsuruo T. Evaluation of tankyrase inhibition in whole cells. Methods Mol Biol 2007; 405: 133–146.
Chen H, Li Y, Tollefsbol TO. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr Pharm Des 2007; 13: 933–962.
McCabe N, Cerone MA, Ohishi T, et al. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene 2009; 28: 1465–1470.
Seimiya H, Muramatsu Y, Ohishi T, et al. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 2005; 7: 25–37.
Shay JW, Wright WE. Mechanism-based combination telomerase inhibition therapy. Cancer Cell 2005; 7: 1–2.
Lu HD, Huang T, Shen WZ, et al. Effect of tankyrase antisense oligonucleotide combined human telomerase reverse transcriptase antisense oligonucleotide on telomere dynamics in human lung adenocarcinoma A549 cells. Ai Zheng 2007; 26: 1164–1169 (Chinese). 187–192